Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML0289

Sigma-Aldrich

Bromfenac sodium

≥98% (HPLC)

Sinónimos:

2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C15H11BrNNaO3
Número de CAS:
91714-93-1
Peso molecular:
356.15
Número MDL:
MFCD03701673
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
329825297
NACRES:
NA.77

Ensayo

≥98% (HPLC)

Formulario

powder

condiciones de almacenamiento

desiccated

color

faintly yellow to dark yellow

solubilidad

H2O: ≥5 mg/mL

temp. de almacenamiento

2-8°C

cadena SMILES

[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c2ccc(Br)cc2

InChI

1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1

Clave InChI

HZFGMQJYAFHESD-UHFFFAOYSA-M

Información sobre el gen

human ... PTGS1(5742) , PTGS2(5743)

Aplicación

Bromfenac sodium has been used:
  • to study its ability to bind to melanin
  • in the synthesis of bromfenac indolinone standard
  • to analyze its permeability in porcine conjunctiva

Acciones bioquímicas o fisiológicas

Bromfenac exhibits antipyretic and prostaglandin synthetase inhibiting properties. It has therapeutic properties against the reduction of ocular pain and inflammation in postoperative cataract patients. Bromfenac acts as an effective agent against allergic conjunctivitis. It has the potential to treat acute muscle pain, osteoarthritis, and rheumatoid arthritis.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID) that inhibits both COX1 and COX2. It is used as an opthalmic analgesic.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID); COX1 and COX2 inhibitor; opthalmic analgesic.

Pictogramas

Skull and crossbones
GHS06

Palabra de señalización

Danger

Frases de peligro

H301

Clasificaciones de peligro

Acute Tox. 3 Oral

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
126M4755V
032M4744V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 1

1 of 1

Dexametasona powder, BioReagent, suitable for cell culture, ≥97%

Sigma-Aldrich

D4902

Dexametasona

Christina Flaxel et al.
Retina (Philadelphia, Pa.), 32(3), 417-423 (2011-08-25)
To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone. This was a single-site, multiinvestigator, prospective, open-label, interventional, Phase II study of patients with new or recurrent exudative/neovascular age-related macular degeneration. Thirty eyes were
Jeffrey S Heier et al.
Retina (Philadelphia, Pa.), 29(9), 1310-1313 (2009-11-26)
To assess vitreous concentrations of nonsteroidal antiinflammatory drugs (NSAIDs) and prostaglandin E(2) in patients treated with NSAIDs before vitrectomy. This was an investigator-masked, randomized, multicenter study. Patients received ketorolac 0.4% 4 times a day, bromfenac 0.09% 2 times a day
Frank A Bucci et al.
Advances in therapy, 28(12), 1089-1095 (2011-11-23)
We compared the prostaglandin E(2) (PGE(2)) inhibition of three topical nonsteroidal antiinflammatory drugs (NSAIDs): ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% at peak dosing levels in patients previously scheduled to undergo phacoemulsification. This was a single-center, double-masked observational study of
Frank A Bucci et al.
Current medical research and opinion, 27(12), 2235-2239 (2011-10-14)
To compare the peak to-aqueous penetration of three nonsteroidal anti-inflammatory drugs: ketorolac tromethamine 0.45%, bromfenac 0.09%, nepafenac 0.1%, and amfenac (the active metabolite of nepafenac) in patients undergoing phacoemulsification. A single center, double-masked study randomized 122 patients to receive one
Koichiro Mukai et al.
Journal of cataract and refractive surgery, 35(9), 1614-1618 (2009-08-18)
To evaluate the efficacy of ophthalmic nonsteroidal and steroidal antiinflammatory drugs in preventing anterior capsule contraction and secondary posterior capsule opacification (PCO) using an experimental cataract model. Department of Ophthalmology, Dokkyo Medical University, Tochigi, Japan. Eight-week-old albino rabbits weighing about
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico